KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Endoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Analysis of the LIBERTY-CD Study.

Bruce E Sands, Stefan Schreiber, Marla C Dubinsky, Geert D'Haens, Bincy P Abraham, Miguel Regueiro, Silvio Danese, Hyunsoo Park, Dong-Hyeon Kim, Young Nam Lee, Stephen B Hanauer, Jean-Frédéric Colombel

Clin Gastroenterol Hepatol 24(4) 1111-1120

PMID41285264
PMCID-
DOI10.1016/j.cgh.2025.11.017
发表日期2025-11-24
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND & AIMS: The efficacy of targeted therapies for patients with Crohn's disease (CD) varies by disease location, with the terminal ileum being the most challenging segment to treat despite its frequent involvement. We investigated the efficacy of subcutaneous infliximab (IFX SC) in patients with moderately to severely active CD according to disease location using data from the phase III LIBERTY-CD trial. METHODS: This analysis included week (W) 10 responders to intravenous IFX induction therapy who were randomized to receive IFX SC 120 mg every 2 weeks or placebo (PBO) during maintenance therapy. Patients were grouped according to baseline disease location (ileum-dominant or colon-dominant), and outcomes were assessed up to W54. Endoscopic response was also evaluated at the segmental level. Factors associated with W54 outcomes were assessed according to disease location. RESULTS: Among 329 patients, 52.6% had colon-dominant CD (n = 173), and 47.4% had ileum-dominant CD (n = 105). Baseline characteristics were comparable between groups. At W54, IFX SC significantly improved all efficacy endpoints vs PBO, even though PBO-treated patients may have experienced residual treatment effects from intravenous IFX induction therapy. Treatment effects were similar regardless of disease location. In both location groups, clinical remission and endoscopic response at W54 correlated with higher serum IFX levels at W14 and W54. Endoscopic responses at W54 were greater with IFX SC vs PBO across all ileocolonic segments, including the terminal ileum, with consistent treatment effect sizes observed throughout each segment. CONCLUSIONS: Although ileal disease is often more treatment resistant, IFX SC maintenance therapy was effective vs PBO regardless of disease location, demonstrating consistent efficacy across segments including the terminal ileum.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。